Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia

Ten healthy volunteers (seven men and three women; mean age=35.2 years, SD=9.2) participated in this study. The subjects were in good health and underwent a brief medical evaluation. The subjects were free of psychiatric disorders on clinical examination and on the Structured Clinical Interview for DSM-III-R (19). All of these subjects had been drug- and alcohol-free for at least 6 months, and all concurrently participated in a separate study examining the effects of ketamine on healthy volunteers.

Fifteen patients (10 men and five women; mean age 33.4 years, SD=9.5) who met the DSM-IV criteria for schizophrenia (N=14) or schizoaffective disorder (N=1) were admitted to the 4th Floor East Patient Care Unit of the National Institutes of Health (NIH) Clinical Center in Bethesda, Md., or the Neurosciences Center of NIH at St. Elizabeths Hospital in Washington, D.C. Two patients were free of antipsychotic drugs, and 13 patients were undergoing pharmacotherapy during the rating period. Antipsychotic drug treatment was with olanzapine (N=6), clozapine (N=2), risperidone (N=3), and fluphenazine (N=2). All patients were clinically stable but symptomatic at the time of assessment.

The healthy volunteers and patients with schizophrenia were gender- and age-matched (age differences: t=0.47, df=23, p=0.64). After a complete description of the study to the subjects, written informed consent was obtained.

Ketamine was administered as a bolus followed by constant infusion over 1 hour to the healthy volunteers in a double-blind, placebo-controlled fashion, as previously described (6, 7, 10).

Formal thought disorder was rated using the Scale for the Assessment of Thought, Language, and Communication to assess specific aspects of thought disorder during a 15-minute interview. Healthy volunteers were rated during infusions of ketamine and placebo. Ratings were conducted by a single experienced investigator (C.M.A.).

To compare ketamine-induced thought disorder with thought disorder in patients with schizophrenia, independent t tests (two-tailed) were conducted with the scores from the Scale for the Assessment of Thought, Language, and Communication obtained from the patients with schizophrenia and the scores obtained from the healthy volunteers during ketamine infusions. Scores from the Scale for the Assessment of Thought, Language, and Communication were analyzed in total and by factors for verbal production and disconnection, factors for positive and negative symptoms, and a unidimensional severity factor (18). Individual items were examined in an exploratory manner. Effect sizes (d) were calculated for patients with schizophrenia and healthy volunteers for total and factor scores on the Scale for the Assessment of Thought, Language, and Communication.

There were no significant differences between the ­total scores for patients with schizophrenia and the total scores for healthy volunteers receiving ketamine on the Scale for the Assessment of Thought, Language, and Communication (t=0.43, df=23, p=0.67, d=0.19). There was no significant difference between the groups’ scores on any of the factors tested on the Scale for the Assessment of Thought, Language, and Communication. The scores for the unidimensional severity factor (t=–0.40, df=23, p=0.69, d=0.18), the paired factors for verbal productivity (t=0.75, df=23, p=0.46, d=0.30) and disconnection (t=0.21, df=23, p=0.84, d=0.10), and the paired factors for positive (t=0.02, df=23, p=0.98, d=0.01) and negative (t=1.10, df=23, p=0.28, d=0.45) symptoms did not differ for the patients with schizophrenic thought disorder and the patients with ketamine-induced thought disorder. Only the scores for one of the 20 individual items on the Scale for the Assessment of Thought, Language, and Communication—perseveration (t=2.13, df=23, p=0.04)—differed significantly for the two groups. This item was not found to be significantly different after use of a Bonferroni correction for the 20 comparison items (figure 1). In patients with schizophrenia and healthy volunteers receiving ketamine, scores for three of the four highest rated items on the Scale for the Assessment of Thought, Language, and Communication—poverty of speech, circumstantiality, and loss of goal—were the same.

Total scores on the Scale for the Assessment of Thought, Language, and Communication for healthy volunteers receiving ketamine did not significantly differ from total scores for a group of clinically stable inpatients with schizophrenia or from factors reflecting both positive and negative symptoms. Three of the four items most affected by ketamine administration—poverty of speech, circumstantiality, and loss of goal—were the same as three of the four highest rated items for patients with schizophrenia.

Our findings are consistent with those of Luby et al. (4), in which PCP-induced thought disorder in a group of healthy volunteers was similar to the disorganization of thought found in a group consisting for the most part of patients with schizophrenia. Similarly, these data are consistent with those of previous studies that demonstrated that ketamine induces a pattern of some schizophrenia-like symptoms in healthy volunteers (7, 8). In contrast, LSD, a serotonin agonist, and amphetamine, a dopamine agonist, induce syndromes that do not, in general, so closely resemble those of chronic schizophrenia, particularly with regard to thought disorder (20, 21). Our data, which suggest that thought disorder induced by NMDA receptor antagonists is strongly reminiscent of the thought disorder found in patients with schizophrenia, support the hypothesis that dysfunction of NMDA receptors is important in schizophrenia.

Several caveats should be considered in the interpretation of this study. Thirteen of the 15 patients with schizophrenia were undergoing treatment with anti­psychotic drugs during the study. Harvey et al. (22), however, found that neuroleptics did not significantly alter the BPRS factor structure of schizophrenic symptoms and that the symptoms of patients who respond to medication do not qualitatively differ from the symptoms of patients who do not respond to medication. Moreover, our clinical experience is that while the intensity of thought disorder may decrease with medication treatment, the profile of the thought disorder is not altered.

Another important issue of this study is group size. Although the number of subjects was somewhat limited, the small effect sizes for key factors including disconnection suggested little overall difference between groups in the underlying dimension of language disorganization. Power analysis based on the effect sizes observed here revealed that a study would require more than 400 subjects to have a power of 0.80 to detect a difference in total scores at α=0.05. Therefore, only with prohibitively large study groups would a significant difference be observed. The more moderate effect size observed with the negative symptom factor of the Scale for the Assessment of Thought, Language, and Communication suggests that ketamine is a better model for the positive, rather than the negative, symptoms of schizophrenia. Given that substantially fewer items are used to calculate scores for negative factors, however, the higher effect size may be merely a function of power.

Finally, although ketamine-induced thought disorder appears to be modulated through non-NMDA mechanisms, several lines of evidence may preclude this possibility. Ketamine binds to the NMDA receptor with an affinity that is at least seven times higher than that for other sites (23–26), and behaviors induced by NMDA receptor antagonists are not blocked by opiate, cholinergic, or monoamine receptor antagonists (27). Moreover, non-NMDA, voltage-gated potassium currents are lessened only at extremely high drug levels, which suggests that low doses of ketamine are selective for the NMDA receptor (28).

In conclusion, we have demonstrated that ketamine-induced thought disorder does not differ significantly from the thought disorder of patients with schizophrenia, as measured by the Scale for the Assessment of Thought, Language, and Communication. Our findings provide additional data that show that ketamine administration in healthy volunteers produces a clinical syndrome with aspects that resemble key symptoms of schizophrenia and lend further support to the hypothesis that NMDA receptor dysfunction is involved in the pathophysiology of schizophrenia.

Received Oct. 9, 1998; revision received Feb. 9, 1999; accepted Feb. 23, 1999. From the Experimental Therapeutics Branch, NIMH, Bethesda, Md. Address reprint requests to Dr. Adler, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Bethesda Ave., Cincinnati, OH 45267-0559; [email protected] (e-mail)